STE Steris
Quality sterilization franchise with better reinvestment than reported, but $253 still prices in near-perfect execution.
The story
Steris is a sterilization and infection-prevention toll-collector. Roughly 70% of revenue is recurring consumables, services and contract sterilization (AST), tied to procedure volumes and device makers' regulatory requirements. Switching costs and validation lock-in make it a durable, mature compounder. Margins are recovering as Cantel integration costs roll off and AST capacity investments start to pay off.
TTM GAAP margin rose to 19.2% from 18.7%, so the target moves up modestly to 22%, consistent with adjusted margins and fading amortization. Sales-to-capital rises from 1.0 to 1.3, a material move: capex ($0.35B) now runs below D&A ($0.49B), and the reported 0.68 is deflated by Cantel goodwill, which overstates the capital needed for incremental growth. The horizon extends from 8 to 10 years to reflect the recurring, regulation-locked consumables base. At $253 the gap to my previous value was nearing 2x, so this re-check against the market is warranted.
Value drivers
| Revenue growth (Y1) | 7.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 22.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.30 |
| Beta | 0.88 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.8% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 6.55B |
| PV of terminal value | 8.12B |
| Equity value | 13.03B |
| ÷ shares → per share | $134.19 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.60B | 7.0% | 19.9% | 982.37M | 332.01M | 650.36M | 597.96M |
| 2 | 7.03B | 6.6% | 20.6% | 1.08B | 332.70M | 751.62M | 635.38M |
| 3 | 7.46B | 6.1% | 21.3% | 1.19B | 330.47M | 859.94M | 668.37M |
| 4 | 7.88B | 5.7% | 22.0% | 1.30B | 325.16M | 974.80M | 696.60M |
| 5 | 8.29B | 5.2% | 22.0% | 1.37B | 316.64M | 1.05B | 690.67M |
| 6 | 8.69B | 4.8% | 22.0% | 1.43B | 304.82M | 1.13B | 681.64M |
| 7 | 9.07B | 4.3% | 22.0% | 1.50B | 289.67M | 1.21B | 669.62M |
| 8 | 9.42B | 3.9% | 22.0% | 1.55B | 271.23M | 1.28B | 654.78M |
| 9 | 9.74B | 3.4% | 22.0% | 1.61B | 249.57M | 1.36B | 637.31M |
| 10 | 10.04B | 3.0% | 22.0% | 1.66B | 224.86M | 1.43B | 617.44M |
Key risks
- Hospital capital-equipment budget cuts or a slowdown in procedure volumes
- Regulatory pressure on ethylene oxide (EtO) sterilization raising AST compliance costs or forcing plant changes
- Multiple compression if growth falls back to mid-single digits while the stock trades near 30x earnings
Catalysts
- AST capacity additions (X-ray/E-beam) converting to high-margin volume
- Continued margin expansion and deleveraging as amortization fades and integration finishes